YORVIPATH Specialised Therapeutics Pharma Pty Ltd
Product name
YORVIPATH
Accepted date
Apr-2024
Active ingredients
palopegteriparatide
Proposed indication
For the treatment of hypoparathyroidism in adults.
Application type
A (new medicine)
Publication date
Apr-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.